HOME >> MEDICINE >> NEWS
Neoadjuvant and adjuvant systemic therapy for breast cancer give equivalent survival, study finds

The timing of systemic therapy--chemotherapy or endocrine therapy--for breast cancer does not appear to affect survival or disease progression. However, women who receive systemic therapy and radiation therapy without surgery may be more likely to experience a recurrence of their cancer compared with women treated with chemotherapy later, according to a new study in the February 2 issue of the Journal of the National Cancer Institute.

Neoadjuvant--also called preoperative or primary--systemic therapy for breast cancer may result in local tumor regression or even in a complete tumor response and may lead to a more limited extent of surgery--from radical mastectomy to some type of breast-conserving surgery--without risking patient survival. For these reasons, interest in the use of neoadjuvant therapy has been increasing.

To investigate how the timing of systemic therapy affects breast cancer outcomes, John P.A. Ioannidis, M.D., of the University of Ioannina School of Medicine in Greece, and colleagues performed a meta-analysis of nine randomized trials that had included nearly 4,000 breast cancer patients. The patients had been treated with systemic therapy either before or after surgery and/or radiation therapy.

There was no difference between neoadjuvant and adjuvant systemic therapy in terms of death, disease progression, or distant disease recurrence. However, neoadjuvant therapy was associated with a 22% increased risk of loco-regional disease recurrence compared with adjuvant therapy. This risk was higher (53%) when radiation therapy was used without surgery.

"[T]his meta-analysis demonstrates the equivalence of neoadjuvant and adjuvant treatments for breast cancer in terms of survival, disease progression, and distant recurrence and shows that an increased risk of loco-regional disease recurrence is associated with neoadjuvant treatment, especially when primary systemic treatment is not accompanied by any surgical interve
'"/>

Contact: Sarah L. Zielinski
jncimedia@oupjournals.org
301-841-1287
Journal of the National Cancer Institute
1-Feb-2005


Page: 1 2

Related medicine news :

1. MRI better than current standard in assessing neoadjuvant chemotherapy for breast cancer
2. Updated adjuvant data presented at SABCS show 30 percent reduction in recurrence
3. Different methods of adjuvant chemotherapy for colorectal cancer have similar outcomes
4. Study supports tailoring adjuvant therapy for early-stage breast cancer
5. Nordic collaboration gives new insights into adjuvant chemotherapy
6. Tumor-targeted immune cells cure prostate cancer in mice without causing systemic immune suppression
7. A blood test may reveal systemic factors that relate to periodontal disease, especially in men
8. Important information to consider about non-systemic cholesterol lowering agents
9. Study shows patch therapy may be as effective as oral medications
10. Novel therapy tested in mice could chase away cat allergies
11. Drug therapy may be comparable to invasive cardiac procedures for elderly patients with heart attack

Post Your Comments:
(Date:7/28/2014)... (PRWEB) July 28, 2014 Community Health ... primary medical, dental, and pharmacy services, has released an ... chronic disease management . Founded in 1983, the ... to those of the county that face barriers to ... To make an appointment at the CHC, click here: ...
(Date:7/28/2014)... South Carolina (PRWEB) July 28, 2014 ... enjoy their first bite of food best, with each ... Over-indulging, the researchers found, can actually serve to sabotage ... overindulge in foods they enjoy, not realizing the effect," ... "This is the argument for moderation, if we needed ...
(Date:7/28/2014)... Myers, Florida (PRWEB) July 28, 2014 ... management business process outsourcing (BPO) for Fortune 500 brands, ... 2,500 jobs across its locations in Wisconsin, California, Florida ... will be based at its Fort Myers campus, and ... available. , The hiring is to support several health-insurance ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 Maternal and ... Allan Tucker Award, which will be presented at the ... on October 29th at the Westmoreland Club in Wilkes-Barre. ... County Commissioner and long-time employee of MFHS. She ... leader, political activist, health advocate, and champion for women, ...
(Date:7/28/2014)... 2014 Labors.at, Austria’s largest and ... Healthcare Relationship Cloud™ to fuel its growth initiatives. ... to 8,000 patients daily and performs up to ... up to doubling its volume within the next ... cutting-edge 10,000 square meter facility pushed our team ...
Breaking Medicine News(10 mins):Health News:Community Health Center of Snohomish Releases Article Focusing on Educating the Chronically Ill About Chronic Disease Management 2Health News:Community Health Center of Snohomish Releases Article Focusing on Educating the Chronically Ill About Chronic Disease Management 3Health News:Large Portions Can Decrease Food Enjoyment, SlimPlate Weight Loss System Puts Focus On Portion Control 2Health News:Large Portions Can Decrease Food Enjoyment, SlimPlate Weight Loss System Puts Focus On Portion Control 3Health News:Alta Resources To Fill Approximately 1,200 Positions In Fort Myers 2Health News:Alta Resources To Fill Approximately 1,200 Positions In Fort Myers 3Health News:Alta Resources To Fill Approximately 1,200 Positions In Fort Myers 4Health News:MFHS Seeking Nominations for Rose Allan Tucker Award 2Health News:Austrian Laboratory Leader, Labors.at, Fuels Growth with the hc1® Healthcare Relationship Cloud™ 2
(Date:7/28/2014)... 2014  ProteinSimple announced today that it has launched ... assay allows users to detect all proteins separated in ... users can analyze proteins without the need for an ... protein analysis as we know it today. First, the Simple ... no messy gels, no transfer tanks, no blots, no ...
(Date:7/28/2014)... und LONDON , July ... , Ziel der Zusammenarbeit sind Entwicklung und Kommerzialisierung ... Plasmaproben zur Steuerung von Therapien mit IRESSA bei ... Neuer Bluttest basiert auf QIAGENs von der ... Rotor-Gene Q, einer Automationsplattform der QIAsymphony-Produktfamilie, laufen  ...
(Date:7/28/2014)... and LONDON , July 28, ... aims to create and commercialize companion diagnostic using genomic ... IRESSA  for non-small cell lung cancer patients  ...   EGFR test and is planned to run on Rotor-Gene Q, member ... Project enabled by AstraZeneca master framework agreement adds to ...
Breaking Medicine Technology:ProteinSimple Says "Never Run a Gel Again!" 2QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 2QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 3QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 4QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 5QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 6QIAGEN und AstraZeneca entwickeln Begleittest auf Basis von Flüssigbiopsien zur erweiterten Bestimmung von EGFR-Mutationen bei Lungenkrebspatienten 7QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 2QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 3QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 4QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 5QIAGEN and AstraZeneca Collaborate to Develop Liquid Biopsy-Based Companion Diagnostic to Advance EGFR Mutation Profiling in Lung Cancer Patients 6
Cached News: